A Possible Novel Anti-Inflammatory Mechanism for the Pharmacological Prolyl Hydroxylase Inhibitor 3,4-Dihydroxybenzoate: Implications for Use as a Therapeutic for Parkinson’s Disease

<table>Iba1 immunostaining of SN sections of mice treated with either saline (Control), DHB, MPTP or DHB + MPTP. (a) Microglia in MPTP-treated mice display a morphological transformation from resting ramified microglia to activated amoeboid like forms with withdrawn processes (indicated by arrows) which is inhibited in the presence of DHB treatment. (b) MPTP treatment leads to a significant increase in the number of activated microglia relative to saline and DHB treated mice. Activated microglia were bilaterally counted under a 40x objective. Data are means ± SEM for 4 mice per group, *<svg height="11.375" id="M33" style="vertical-align:-0.1638pt" version="1.1" viewbox="0 0 58.712502 11.375" width="58.712502" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,11.112)"><use xlink:href="#x1D443"></use></g><g transform="matrix(.017,-0,0,-.017,15.582,11.112)"><use xlink:href="#x3C"></use></g><g transform="matrix(.017,-0,0,-.017,30.286,11.112)"><use xlink:href="#x30"></use></g><g transform="matrix(.017,-0,0,-.017,38.446,11.112)"><use xlink:href="#x2E"></use></g><g transform="matrix(.017,-0,0,-.017,42.321,11.112)"><use xlink:href="#x30"></use></g><g transform="matrix(.017,-0,0,-.017,50.481,11.112)"><use xlink:href="#x35"></use></g>
</svg> compared to saline group.</table>

Parkinson’s Disease

fig8

Figure 8

Figure 8: A Possible Novel Anti-Inflammatory Mechanism for the Pharmacological Prolyl Hydroxylase Inhibitor 3,4-Dihydroxybenzoate: Implications for Use as a Therapeutic for Parkinson’s Disease 

Figure 8 | A Possible Novel Anti-Inflammatory Mechanism for the Pharmacological Prolyl Hydroxylase Inhibitor 3,4-Dihydroxybenzoate: Implications for Use as a Therapeutic for Parkinson’s Disease 